Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-086267 · Präparat HOS-083284
Bedaquiline No interaction study is available with ritonavir only. In an interaction study of
single-dose bedaquiline and multiple dose lopinavir/ritonavir, the AUC of
bedaquiline was increased by 22%. This increase is likely due to ritonavir and a
more pronounced effect may be observed during prolonged co-administration. Due
to the risk of bedaquiline related adverse events, co-administration should be
avoided. If the benefit outweighs the risk, co-administration of bedaquiline with
ritonavir must be done with caution. More frequent electrocardiogram monitoring
and monitoring of transaminases is recommended (see section 4.4 and refer to the
bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bedaquiline (HOS-086268) lopinavir (HOS-086269)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 13fd00e555c9ee84479a09bd0b5efb043b6c724aac394be9d70ecfdae9c81259 · Zeichen 32476–33474 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086274 · Präparat HOS-083284
Delamanid No interaction study is available with ritonavir only. In a healthy volunteer drug
interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir
400/100 mg twice daily for 14 days, the exposure of the delamanid metabolite DM-
6705 was 30% increased. Due to the risk of QTc prolongation associated with
DM-6705, if co-administration of delamanid with ritonavir is considered necessary,
very frequent ECG monitoring throughout the full delamanid treatment period is
recommended (see section 4.4 and refer to the delamanid SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d51b806ff99e8d1618d75c76ca6e8311839d662681e9f612cede7434818e5d48 · Zeichen 35266–36091 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-086344 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 3c27321459baa7b0705afde806e8b539a0a25a4b47e2383e187fb6fd8f60bfb2 · Zeichen 60628–61278 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-086450 · Präparat HOS-083284
49
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co-administered Medicinal Dose of Effect on Co- Effect on Co-
Products (mg) NORVIR administered administered
(mg) Medicinal Medicinal
Products Products Cmax
AUC
Bedaquiline No interaction study is available with ritonavir only. In an interaction study of single-dose
bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was increased
by 22%. This increase is likely due to ritonavir and a more pronounced effect may be
observed during prolonged co-administration. Due to the risk of bedaquiline related
adverse events, co-administration should be avoided. If the benefit outweighs the risk,
co-administration of bedaquiline with ritonavir must be done with caution. More frequent
electrocardiogram monitoring and monitoring of transaminases is recommended (see
section 4.4 and refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bedaquiline (HOS-086268) lopinavir (HOS-086269)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 31738bbc16b4c93df384898192dda583972908126d2b2e301991a8d91064b893 · Zeichen 33608–35264 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-086453 · Präparat HOS-083284
Delamanid No interaction study is available with ritonavir only. In a healthy volunteer drug
interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg
twice daily for 14 days, the exposure of the delamanid metabolite DM-6705 was 30%
increased. Due to the risk of QTc prolongation associated with DM-6705, if
co-administration of delamanid with ritonavir is considered necessary, very frequent ECG
monitoring throughout the full delamanid treatment period is recommended (see section
4.4 and refer to the delamanid SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 57d1ec46e3f48a129fc821449bdd908ff2fe642333cf7b91a4da4b7a4e61e4b5 · Zeichen 36334–37130 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-086497 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 4de66caff969925d9ad024610386f020326d8902794177858246b69263b12d3c · Zeichen 62968–63646 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.